Press release BUDAPEST, HUNGARY, August 14, 2023/ EINPresswire.com/ — VRG Therapeutics(VRG Tx), a pioneering biotechnology research and development company specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products, is pleased to announce that it has successfully secured a €5 million investment deal. The funding was led by the Budapest based Széchenyi Funds (SZTA) […]
We proudly announce the publication of our first paper in Journal of Biological Chemistry (JBC) related to our chlorotoxin analogue (CTXA) development. We use our patented chlorotoxin analogues for targeting CAR-T cells to cure patient suffering from glioblastoma multiforme (GBM). Publication link: https://www.jbc.org/article/S0021-9258(23)02026-4/fulltext
Press release BUDAPEST, HUNGARY, May 26, 2023/ EINPresswire.com/ — VRG Therapeutics, a biotechnology R&D company focused on peptide-based pharmaceuticals and cellular & gene therapy (CGT) products has announced that their exceptionally selective Kv1.3 inhibitor peptide showed efficacy in a delayed-type hypersensitivity animal model. VRG Tx’s lead compound has been developed on the company’s ISEP platform […]
Our chlorotoxin-analog (CTXA) targeted CAR T asset is not only strong by scientific means but also holds strong IP protection. The project reached an important milestone: we received the International Preliminary Report on Patentability for our patent application (PCT/HU2021/050075). The result is: all claims have been accepted in terms of all requirements of patentability! We’ll […]
In order to continue the progress of our portfolio, we have separated from our mother company and launched VRG Therapeutics, a company fully dedicated to R&D. Stay with us on our journey!
VRG is planning to apply for a Pathfinder Open grant (HORIZON-EIC-2023-PATHFINDEROPEN-01-01) and looking for partners active on the following fields: – Development and production of AAV-s for viral transduction of genetic material to CNS neurons.– Development and production of electrodes to be applied in neurosurgery or devices for microinjection. The device we envisage would be […]
We are happy to share that we participate Bio-Europe on October 24–26, 2022 in Leipzig, Germany. We are looking for investors/partners for our forerunning GBM targeting CTXA-CAR-T project. In addition, you may learn more about our gene therapy based chemogenetic program in CNS indication which is now available for initial funding.Meet our Head of CMC […]
We are happy to share that we have become a member of Alliance for Regenerative Medicine (ARM). ARM is the most prestigious community for companies active in the Cell and Gene Therapy (CGT) field. We consider this as an important step on the road towards fulfilling our mission to cure diseases via targets and MoAs […]
We’re expanding our network towards academic research: VRG will join Innovation Marketplace and Career Day of Eötvös Loránd University, Faculty of Science on 13 October. Our BD and Project Manager, Tamás Kitka will give a company presentation and participate a roundtable discussion. Looking forward to meet our future research partners there! Cell and Gene Meeting […]
Press release DREADDs are exclusively activated by their pharmaceutical ligand, the so-called actuator. CNS-delivered artificial DREADDs have no physiological effects without their actuator, offering a flexible and adaptive control of the timing and intensity of the effect. This technique can be employed to develop a safe, adjustable alternative of current neurosurgery techniques, such as deep […]
